VDC-Banner-new_468
zrt-banner2
grassroots-banner
sunfriend-banner

Information on the latest vitamin D news and research.

Find out more information on deficiency, supplementation, sun exposure, and how vitamin D relates to your health.

Multiple myeloma

Multiple myeloma (MM) is a cancer of the plasma cells. They are white blood cells that normally produce antibodies.

Multiple myeloma affects about 20,000 in the United States each year and kills about 11,000.

Risk factors

Risk factors of multiple myeloma may include:

  • Obesity
  • Diet, with fruit and vegetable consumption associated with reduced risk
  • Environmental toxins (radiation, hydrocarbon chemicals)

Multiple myeloma occurs twice as often in African-Americans than in white Americans.

Sunlight exposure and multiple myeloma risk

There is evidence that solar ultraviolet-B (UVB) light reduces the risk of multiple

myeloma. Several geographical studies found reduced rates of multiple myeloma in regions with higher solar UVB doses. Also, a study of teachers in California found greatly reduced risk of multiple myeloma for those living in regions of higher UVB doses.

Vitamin D and multiple myeloma

Vitamin D levels

There is limited information on the benefits of vitamin D and multiple myeloma risk. According to two U.S. studies:

  • People with more advanced cases of multiple myeloma at time of diagnosis had lower vitamin D levels. However, people with advanced multiple myeloma may spend more time indoors and therefore have less sun exposure.
  • A Harvard study of U.S. doctors found a slightly reduced risk of multiple myeloma for those with higher vitamin D levels.

How vitamin D works

Multiple myeloma causes an increased production of matrix metalloproteinases (MMPs). MMPs are enzymes that enable cancer cells to migrate into other tissues. The hormonal version of vitamin D, calcitriol, reduces MMP production and the ability of cancer to spread.

Prevention

High levels of vitamin D are associated with a lower risk of multiple myeloma in both observational studies of individuals and geographic studies of populations.

Treatment

Multiple myeloma is considered incurable. A study in Baltimore, Maryland, found no link between vitamin D level and multiple myeloma activity. However, in 10% to 20% of patients with multiple myeloma, vitamin D supplements reduced muscle weakness, fatigue, and chronic bone pain.

Acknowledgements

This evidence summary was written by:

William B. Grant, Ph.D.
Sunlight, Nutrition, and Health Research Center (SUNARC)
P.O. Box 641603
San Francisco, CA 94164-1603, USA
www.sunarc.org
wbgrant@infionline.net

Last updated

June 2011

References

  1. Badros, A. Goloubeva, O. Terpos, E. Milliron, T. Baer, M. R. Streeten, E. Prevalence and significance of vitamin D deficiency in multiple myeloma patients. Br J Haematol. 2008 Jul; 142 (3): 492-4.
  2. Barille, S. Akhoundi, C. Collette, M. Mellerin, M. P. Rapp, M. J. Harousseau, J. L. Bataille, R. Amiot, M. Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood. 1997 Aug 15; 90 (4): 1649-55.
  3. Barille, S. Collette, M. Bataille, R. Amiot, M. Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood. 1995 Oct 15; 86 (8): 3151-9.
  4. Becker, N. Epidemiology of multiple myeloma. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. 2011; 18325-35.
  5. Boscoe, F. P. Schymura, M. J. Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993-2002. BMC Cancer. 2006; 6264.
  6. Chang, E. T. Canchola, A. J. Cockburn, M. Lu, Y. Wang, S. S. Bernstein, L. Clarke, C. A. Horn-Ross, P. L. Adulthood residential ultraviolet radiation, sun sensitivity, dietary vitamin D, and risk of lymphoid malignancies in the California Teachers Study. Blood. 2011 May 26;
  7. Diamond, T. Golombick, T. Manoharan, A. Vitamin D status may effect the skeletal complications of multiple myeloma. Am J Hematol. 2010 Apr; 85 (4): 302-3.
  8. Grant, W. B. Ecologic studies of solar UV-B radiation and cancer mortality rates. Recent Results Cancer Res. 2003; 164371-7.
  9. Grant, W. B. An ecologic study of cancer mortality rates in Spain with respect to indices of solar UVB irradiance and smoking. Int J Cancer. 2007 Mar 1; 120 (5): 1123-8.
  10. Grant, W. B. Effect of interval between serum draw and follow-up period on relative risk of cancer incidence with respect to 25-hydroxyvitamin D level; implications for meta-analyses and setting vitamin D guidelines. Dermato-endocrinology. 2011; 3 (3):
  11. Holick, M. F. Multiple myeloma and cancer: is there a D-lightful connection?. Am J Hematol. 2009 Jul; 84 (7): 393-4.
  12. Hosgood, H. D., 3rd Baris, D. Zahm, S. H. Zheng, T. Cross, A. J. Diet and risk of multiple myeloma in Connecticut women. Cancer Causes Control. 2007 Dec; 18 (10): 1065-76.
  13. Imseis, R. E. Palmieri, G. M. Holbert, J. M. Leventhal, M. R. Sebes, J. I. Effect of calcitriol and pamidronate in multiple myeloma. Am J Med Sci. 1999 Jul; 318 (1): 61-6.
  14. Jezierska, A. Motyl, T. Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Medical science monitor : international medical journal of experimental and clinical research. 2009 Feb; 15 (2): RA32-40.
  15. Khuder, S. A. Mutgi, A. B. Meta-analyses of multiple myeloma and farming. Am J Ind Med. 1997 Nov; 32 (5): 510-6.
  16. Laroche, M. Lemaire, O. Attal, M. Vitamin D deficiency does not alter biochemical markers of bone metabolism before or after autograft in patients with multiple myeloma. Eur J Haematol. 2010 Jul; 85 (1): 65-7.
  17. Lawson-Matthew, P. Clayton, J. Guilland-Cumming, D. Yates, A. Preston, E. Greaves, M. Kanis, J. A. Vitamin D metabolism in myeloma. Br J Haematol. 1989 Sep; 73 (1): 57-60.
  18. Lim, U. Freedman, D. M. Hollis, B. W. Horst, R. L. Purdue, M. P. Chatterjee, N. Weinstein, S. J. Morton, L. M. Schatzkin, A. Virtamo, J. Linet, M. S. Hartge, P. Albanes, D. A prospective investigation of serum 25-hydroxyvitamin D and risk of lymphoid cancers. Int J Cancer. 2009 Feb 15; 124 (4): 979-86.
  19. Mahindra, A. Cirstea, D. Raje, N. Novel therapeutic targets for multiple myeloma. Future oncology. 2010 Mar; 6 (3): 407-18.
  20. Mahindra, A. Cirstea, D. Raje, N. Novel therapeutic targets for multiple myeloma. Future oncology. 2010 Mar; 6 (3): 407-18.
  21. Ng, A. C. Kumar, S. K. Rajkumar, S. V. Drake, M. T. Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. Am J Hematol. 2009 Jul; 84 (7): 397-400.
  22. Paduch, R. Kandefer-Szerszen, M. Vitamin D, tamoxifen and beta-estradiol modulate breast cancer cell growth and interleukin-6 and metalloproteinase-2 production in three-dimensional co-cultures of tumor cell spheroids with endothelium. Cell Biol Toxicol. 2005 Sep-Nov; 21 (5-6): 247-56.
  23. Papapetrou, P. D. Bergi-Stamatelou, M. Karga, H. Thanou, S. Hypercalcemia due to sun exposure in a patient with multiple myeloma and elevated parathyroid hormone-related protein. Eur J Endocrinol. 2003 Mar; 148 (3): 351-5.
  24. Robien, K. Cutler, G. J. Lazovich, D. Vitamin D intake and breast cancer risk in postmenopausal women: the Iowa Women’s Health Study. Cancer causes & control : CCC. 2007 Sep; 18 (7): 775-82.
  25. Segarra, M. Lozano, E. Corbera-Bellalta, M. Vilardell, C. Cibeira, M. T. Esparza, J. Izco, N. Blade, J. Cid, M. C. Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways. Haematologica. 2010 Mar; 95 (3): 456-63.
  26. Tokar, E. J. Webber, M. M. Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells. Clin Exp Metastasis. 2005; 22 (3): 275-84.
  27. Waxman, A. J. Mink, P. J. Devesa, S. S. Anderson, W. F. Weiss, B. M. Kristinsson, S. Y. McGlynn, K. A. Landgren, O. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood. 2010 Dec 16; 116 (25): 5501-6.
  28. Wigington, D. P. Strugnell, S. A. Knutson, J. C. Pamidronate and 1,24(S)-dihydroxyvitamin D2 synergistically inhibit the growth of myeloma, breast and prostate cancer cells. Anticancer Res. 2005 May-Jun; 25 (3B): 1909-17.

Comments are closed.